Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.

Herr MM, Torka P, Zhang Y, Wallace PK, Tario JD Jr, Repasky EA, Chen GL, Ho CM, Balderman SR, Ross M, Paiva B, Hernandez-Ilizaliturri FJ, McCarthy PL, Hahn T.

Bone Marrow Transplant. 2019 Jun 21. doi: 10.1038/s41409-019-0591-4. [Epub ahead of print] Erratum in: Bone Marrow Transplant. 2019 Aug 30;:.

PMID:
31227776
2.

Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.

Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG.

Biol Blood Marrow Transplant. 2008 Jul;14(7):741-7. doi: 10.1016/j.bbmt.2008.04.004.

3.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK.

J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.

PMID:
30615550
4.

Mantle Cell Lymphoma: Which Patients Should We Transplant?

Gerson JN, Barta SK.

Curr Hematol Malig Rep. 2019 Aug;14(4):239-246. doi: 10.1007/s11899-019-00520-0. Review.

PMID:
31218478
5.

Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.

Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ.

Biol Blood Marrow Transplant. 2000;6(5A):555-62.

PMID:
11071261
6.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R.

Ann Oncol. 2018 Mar 1;29(3):724-730. doi: 10.1093/annonc/mdx791.

7.

Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma.

Procházka V, Gawande RS, Cayci Z, Froelich JW, Cao Q, Wilke C, Dusenbery K, Weisdorf DJ, Bachanova V.

Biol Blood Marrow Transplant. 2018 Jan;24(1):64-70. doi: 10.1016/j.bbmt.2017.09.006. Epub 2017 Sep 20.

8.

Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.

Yuan S, Palmer JM, Tsai NC, Dagis A, Nademanee A, Wang S.

Hematol Oncol. 2017 Sep;35(3):281-287. doi: 10.1002/hon.2286. Epub 2016 Feb 29.

PMID:
26928577
9.

Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.

Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN.

Br J Haematol. 2013 Sep;162(5):648-56. doi: 10.1111/bjh.12451. Epub 2013 Jul 6.

10.

Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation.

Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N.

J Cancer. 2017 Mar 25;8(6):1009-1017. doi: 10.7150/jca.16870. eCollection 2017.

11.

A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.

Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP Jr, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS.

Biol Blood Marrow Transplant. 2011 Jul;17(7):987-94. doi: 10.1016/j.bbmt.2010.10.016. Epub 2010 Oct 20.

12.

Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma.

El-Asmar J, Rybicki L, Bolwell BJ, Kharfan-Dabaja MA, Dean R, Hamilton BK, Hanna R, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Hill BT, Majhail NS.

Biol Blood Marrow Transplant. 2019 Sep 13. pii: S1083-8791(19)30622-6. doi: 10.1016/j.bbmt.2019.09.012. [Epub ahead of print]

PMID:
31525493
13.

Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.

Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, Montoto S, Hari PN.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1740-4. doi: 10.1016/j.bbmt.2013.09.018. Epub 2013 Oct 3.

14.

High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.

Nademanee A, Palmer JM, Popplewell L, Tsai NC, Delioukina M, Gaal K, Cai JL, Kogut N, Forman SJ.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1481-9. doi: 10.1016/j.bbmt.2011.02.008. Epub 2011 Feb 19.

15.

Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma.

Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK, Yuan J.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):94-102. doi: 10.1016/j.ijrobp.2017.05.007. Epub 2017 May 15.

16.

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.

17.

Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.

Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1473-1477. doi: 10.1016/j.bbmt.2017.05.020. Epub 2017 May 22.

18.

Blood graft composition after plerixafor injection in patients with NHL.

Varmavuo V, Mäntymaa P, Nousiainen T, Valonen P, Kuittinen T, Jantunen E.

Eur J Haematol. 2012 Aug;89(2):128-35. doi: 10.1111/j.1600-0609.2012.01794.x. Epub 2012 May 24.

PMID:
22536949
19.
20.

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A.

J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17.

Supplemental Content

Support Center